miR-210-3p Impairs Pancreatic β-Cell Function by Targeting Dtx1 in Gestational Diabetes Mellitus

Xiaohui Cao1, Bin Lu2, Ying Gu3

  • 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Canglang District, Suzhou, 215006 Jiangsu, China; Department of Obstetrics, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, Jiangsu 214002, China.

Insights

MicroRNA-210-3p (miR-210-3p) is overexpressed in gestational diabetes mellitus (GDM), impairing pancreatic beta cell function by targeting Dtx1. This research offers a new therapeutic strategy for GDM.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • Gestational diabetes mellitus (GDM) poses significant risks to maternal and infant health.
  • MicroRNA-210-3p (miR-210-3p) is implicated in various diseases, but its role in GDM remains unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism and clinical significance of miR-210-3p in GDM.
  • To investigate the regulatory role of miR-210-3p on pancreatic beta cell function in GDM.

Main Methods:

  • Utilized a GDM mouse model to assess miR-210-3p expression in pancreatic tissue.
  • Employed bioinformatics analysis to identify miR-210-3p targets, followed by in vitro and in vivo rescue experiments.
  • Assessed pancreatic beta cell viability, apoptosis, insulin expression, and blood lipid profiles (TG, TC, HDL).

Main Results:

  • miR-210-3p was significantly overexpressed in the pancreas of GDM mice.
  • miR-210-3p impaired pancreatic beta cell viability and function by targeting and downregulating Dtx1.
  • Downregulation of Dtx1 affected insulin expression and key signaling pathways (Akt, mTOR, 4E-BP1, SGK1).
  • miR-210-3p regulated GDM-associated blood lipid levels via Dtx1 modulation.

Conclusions:

  • miR-210-3p promotes GDM progression by suppressing Dtx1, leading to impaired pancreatic beta cell function.
  • Targeting miR-210-3p presents a potential novel therapeutic strategy for managing GDM.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
232
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.4K